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IMPAK REGIMEN YANG MENGANDUNGI INSULIN BERBANDING TERAPI 
KOMBINASI ANTIDIABETIK ORAL KE ATAS HASIL AKHIR KUALITI 
HIDUP BERKAITAN KESIHATAN, EKONOMIK, DAN KLINIKAL DALAM 
PESAKIT DIABETIS JENIS 2 YANG TIDAK TERKAWAL 
 
ABSTRAK 
 
Penyakit Diabetes Mellitus (DM) Jenis 2 adalah progresif dan kawalan glukos 
darah akhirnya akan menjadi lebih buruk kerana fungsi sel-sel beta pankreatik akan 
menurun.  Monoterapi dengan antidiabetik oral tidak akan berpanjangan dan akan 
disusuli dengan dua hingga tiga antidiabetik oral sebagai terapi kombinasi, dan akhirnya 
pesakit DM Jenis 2 akan memerlukan terapi insulin eksogenus.  Kajian ini 
membandingkan penambahan dan penukaran terapi kepada insulin dengan terapi 3  
antidiabetik oral dengan mengukur 3 parameter hasil akhir iaitu klinikal, humanistik dan 
ekonomi.  Kajian ini menggunakan reka bentuk kajian kohort dengan melakukan 
pemerhatian selama 6 bulan terhadap pesakit dengan kawalan glukos darah yang buruk 
di Dr Sardjito Hospital, Yogyakarta, Indonesia.  Subjek kajian adalah pesakit yang 
sanggup menukar kepada terapi insulin (Kumpulan 1) dan pesakit yang menolak 
cadangan menukar kepada terapi insulin dan terus menggunakan kombinasi terapi 
dengan sulfonylurea, metformin dan akarbos (Kumpulan 2).  Keberkesanan terapi 
dilakukan dengan mengukur paras HbA1c, glukos plasma semasa berpuasa (FPG), dan  
glukos plasma postprandial (PPG), tekanan darah dan profail lipid bagi setiap kumpulan 
terapi pada tahap awal, bulan ke tiga dan bulan ke enam. Ukuran perbezaan nilai kualiti 
hidup pesakit telah dilakukan dengan mengira purata nilai  DQLCTQ bagi setiap 
kumpulan terapi.  Analisis keberkesanan kos telah dilakukan daripada perspektif institusi 
dengan membandingkan kos perubatan langsung bagi tempoh 6 bulan dan keberkesanan 
terapi telah diukur berdasarkan peratus pesakit yang mencapai sasaran glisemik.  
Penilaian keberkesanan menunjukkan pesakit yang menukar kepada terapi insulin adalah 
lebih berkesan dalam mengawal paras glukos darah berbanding dengan terapi 3 
antidiabetik oral.  Insiden hipoglisemik adalah 36.36% bagi kumpulan 1 dan 28.57% 
bagi kumpulan 2.  Insiden kesan sampingan gastrousus lebih tinggi bagi kumpulan 2 
(67.35%) berbanding dengan kumpulan 1 (18.18%).  Purata skor kualiti hidup bagi 
xix 
 
pesakit DM Jenis 2 adalah 77.23%.  Pesakit DM Jenis 2 dengan kawalan glisemik yang 
buruk, terapi 3 antidiabetik  oral dan 2 atau lebih kombinasi mempunyai kualiti hidup 
yang lebih rendah berbanding dengan pesakit yang mempunyai kawalan glisemik yang 
baik dan pesakit dengan terapi insulin dan tanpa komplikasi.  Pesakit yang menukar 
kepada terapi insulin menunjukkan peningkatan skor kualiti hidup yang signifikan 
(p=0.001) selepas 6 bulan.  Manakala, bagi pesakit dengan terapi 3 antidiabetik oral, 
skor kualiti hidup menurun tetapi tidak signifikan secara statistic.  Penambah baikan 
kawalan glisemik menggunakan terapi insulin akan meningkatkan kos rawatan drug 
berbanding dengan kepada penggunaan kombinasi sulfonylurea, metformin dan akarbos.  
Analisis keberkesanan kos menunjukkan hasil kumpulan insulin terapi adalah lebih 
berkesan dalam mengawal paras glukosa dalam darah dan meningkatkan kualiti hidup 
pesakit, tetapi ia memerlukan lebih tinggi kos perubatan ($ 2,959.25 setiap% tambahan 1 
pesakit yang mencapai HbA1c sasaran untuk 6 bulan). 
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HYPOGLYCAEMIC AGENT THERAPY ON HEALTH-RELATED QUALITY 
OF LIFE, ECONOMIC, AND CLINICAL OUTCOMES IN POORLY 
CONTROLLED TYPE 2 DIABETES OUTPATIENTS IN YOGYAKARTA 
 
ABSTRACT 
 
Type 2 Diabetes Mellitus (DM) is a progressive disease, and blood glucose 
control finally will get poorer because the function of pancreatic beta cells will decrease. 
Monotherapy with oral antidiabetics will not be effective for long so it is followed by 
two to three oral antidiabetics as combination therapy, and finally, type 2 DM patients 
will need exogenous insulin therapy. This research compared the addition and switching 
of therapy to insulin with triple oral therapy measuring three outcome parameters, i.e., 
clinical, humanistic and economic outcomes. This research applied cohort study designs 
by conducting six-month observations on the poor blood-glucose-control patients in Dr 
Sardjito Hospital, Yogyakarta, Indonesia. The research subjects were the patients who 
were willing to change the therapy to insulin (Group 1) and the patients who refused to 
use insulin and kept on using therapy combination with sulfonylurea, metformin, and 
acarbose (Group 2). The measurement of effectiveness was conducted by calculating the 
HbA1c, fasting plasma glucose (FPG), and postprandial plasma glucose (PPG) levels, 
blood pressure and lipid profile of each therapy group at baseline, third month and sixth 
month. The measurement of the differences of the quality of life values of the patients 
was conducted by counting the average of the Diabetes Quality of Life Clinical Trial 
Questionnaire scores of each therapy group. Cost-effectiveness analysis was performed 
from the hospital perspective by comparing direct medical costs during the six month 
period and the effectiveness of the therapy which was measured based on the percentage 
xxi 
 
of patients who achieved the glycaemic target. The results indicates that patients who 
switched the therapy to insulin were more effective in controlling blood glucose levels 
than triple oral therapy. However, hypoglycaemic incidents were 36.36% in group 1, and 
28.57% in group 2. A higher incidence of gastrointestinal side effects occurred in group 
2 (67.35%) than in group 1 (18.18%). The average quality of life scores of type 2 DM 
patients was 77.23%. Type 2 DM patients with poor glycaemic control, triple oral 
therapy and two or more complications have a lower quality of life than patients with 
good glycaemic control, and patients with insulin therapy and without complications. 
Patients who switched therapy to insulin indicated a significant increase in quality of life 
(p< 0.001) after 6 months. Meanwhile, for patients with triple oral therapy, the scores of 
quality of life decreased although it was insignificant. The cost-effectiveness analysis 
shows the result that the insulin therapy group is more effective in controlling blood 
glucose levels and improving the patient’s quality of life, but it requires higher direct 
medical costs ($ 2,959.25 per additional 1% of patients who achieved target HbA1c for 6 
months). 
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CHAPTER 1 
 GENERAL INTRODUCTION 
 
1.1 BACKGROUND 
Diabetes Mellitus (DM) is categorized as one of the burdensome and expensive 
chronic diseases due to its increasing prevalence annually, either in Indonesia or in many 
other countries in the world. The World Health Organization states that the number of 
the world’s population suffering from diabetes in 2000 was 171 million and it is 
predicted that the number will increase, reaching 366 million in the year 2030 (Wild et 
al.,  2004). Ten countries that have the highest prevalence of diabetes are India, China, 
USA, Indonesia, Japan, Pakistan, Russia, Brazil, Italy and Bangladesh. In developing 
countries, diabetes mellitus frequently occurs at productive ages, from the age of 35 to 
64 years. Diabetes is one of the premature illnesses and cause of death in many 
countries, particularly due to increases of cardiovascular complications. The number of 
deaths due to diabetes per year is approximately 3.2 million (WHO, 2010). 
 Diabetes can cause many complications, both macrovascular and microvascular, 
and it requires comprehensive and long-term treatment and control. This causes diabetes 
treatment to be expensive, not only for the patient or the family, but also for the 
healthcare system. A study in India estimated that 25% of family income is allotted for 
diabetes treatment in a case of a diabetic adult in a low-income Indian family 
(Ramachandran et al., 2007). On the other hand, 10% of the family income is allotted for 
diabetes treatment in the case of a diabetic child in a USA family (WHO, 2010). Overall, 
direct healthcare cost for diabetes ranges from 2.5% to 15% of the annual healthcare 
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budget, depending on the diabetes prevalence in each country and the availability of 
existing therapies. Based on the research conducted in 25 countries in Latin America, the 
cost of productivity lost due to diabetes is five times bigger than its direct healthcare cost 
(WHO, 2010). Diabetes and its complications bring about significant economic effects 
on the individual, family, healthcare system and country. As an example, WHO 
estimates that an amount of $558 billion of China’s national income is spent on heart 
disease, stroke and diabetes (WHO, 2010).  
 Based on the survey carried out by WHO, Indonesia ranks fourth with the largest 
number of diabetics in the world after India, China and the USA (Stephen and Murray, 
2004). With the prevalence of 8.6% of the population, it was predicted that in the year 
1995 there would be 4.5 millions diabetics and this number will increase to 12.4 million 
by 2025. Based on the data of the Ministry of Health, the number of diabetics, both the 
outpatients as well as hospitalized patients, ranks first among all endocrine diseases, 
while 4% of pregnant women suffer from gestational diabetes (WHO, 2005). 
Epidemiologically, it is predicted the prevalence of DM in Indonesia will reach 21.3 
million people in 2003 (ADA, 2004). The results of Basic Health Research (Riskesdas) 
in 2007 indicated that the proportion of the causes of death due to DM in the age group 
of 45-54 years in urban areas ranks second, with a percentage of 14% (Ministry of 
Health Republic of Indonesia, 2009). Meanwhile, DM ranks sixth in rural areas with a 
percentage of 5.8%. Based on 2007 Riskesdas results, the national prevalence of DM 
obtained through blood glucose check on the population aged >15 years old in urban 
areas is as high as 5.7%. 
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 In Indonesia, health expenses are increasing annually. The percentage of national 
expenditure in the health sector in 2005 amounted to 0.81% of the Gross Domestic 
Product. Despite its increase to 1.09% of GDP in 2007, it has not reached 5% of GDP, as 
recommended by WHO (Ministry of Health Republic of Indonesia, 2009). Similar to the 
health budget in 2004, a total amount of IDR 5.54 trillion was allotted to the state budget 
in Indonesia. This increased in 2007 to  IDR 18.75 trillion, but its percentage of the 
entire state budget has not increased and is still around 2.6%-2.8%. Government 
spending for healthcare continues to rise. However, the contribution of government 
spending for healthcare is still small, as much as 38% of total health expenses.  
The increase in medical cost is caused by the application of advanced 
technology, patterns of direct cash payments to health providers, patterns of chronic and 
degenerative diseases, as well as inflation. The increase in healthcare cost is increasingly 
difficult to overcome with the ability of the government and community in providing 
funds. The rising costs threaten the access and quality of healthcare and solutions should 
therefore be sought to overcome the health financing problem. Financing of public 
healthcare as public good becomes the responsibility of government, whereas the 
financing of individual healthcare is private in nature. Healthcare financing for the poor 
and deprived community becomes the responsibility of the government. Individual 
healthcare funding is administered through healthcare insurance with social insurance 
mechanisms (Ministry of Health Republic of Indonesia, 2009). Even though private 
health insurance and government programmess cover a growing portion of drug 
expenditure, a sizeable amount of drug costs is still paid directly by consumers. The 
costs of pharmaceuticals and pharmacy services have, therefore, become an important 
issue to patients, third-party payers, and governments alike.  
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Health care practitioners, regardless of practice setting, can benefit from 
applying the principles and methods of pharmacoeconomics to their daily practice 
settings. Applied pharmacoeconomics is defined as putting pharmacoeconomic 
principles, methods, and theories into practice to quantify the value of pharmacy 
products and pharmaceutical care services used in real-world environments. Today’s 
cost-sensitive health care environment has created a competitive and challenging 
workplace for clinicians. Competition for diminishing resources has necessitated that the 
appraisal of health care goods and services extends beyond evaluations of safety and 
efficacy and considers the economic impact of these goods and services on the cost of 
health care. Selecting the most cost-effective drugs for an organizational formulary is 
important. However, it is equally important to determine the most appropriate way to use 
and prescribe these agents. Hence, developing and implementing appropriate use 
guidelines or policies based on sound pharmacoeconomic data can have a great impact 
on influencing prescribing patterns (Sanchez, 2005). 
DM can cause complications in various organs such as the eyes, kidneys and 
nerves, thus it significantly increases morbidity and mortality. Complications, both 
microvascular and macrovascular, like hypertension and dyslipidemia that occur in 
patients with DM is a risk factor for cardiovascular disorders. These factors contribute to 
the increased occurrence of disease and death, which significantly becomes a burden on 
healthcare systems. The risk of heart failure in diabetic patients increases, with the 
relative risk increased by 10-15% per unit increase of HbA1c. Heart failure occurs in 
25%-40% of adult diabetic patients. Heart failure patients who are also diabetics usually 
have poor outcomes, thus increasing the number of visits to hospitals (Eurich et al., 
2007). 
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 The objective of therapy in diabetics is to avoid the occurrence of secondary 
diseases by optimizing blood glucose levels and maintaining patients’ quality of life 
(Huang et al., 2006). Type 2 DM is a chronic disease that affects the general health and 
well being of patients. DM treatments, such as a strict diet, daily use of oral medications 
or insulin antidiabetics, affect the patients’ health-related quality of life (HRQoL). 
Besides, long term complications such as nephropathy, neuropathy, heart disease and 
stroke will affect patients' health. Thus, they bring negative effects on patients’ Quality 
of Live (QoL) (Redekop et al., 2002). The mortality rate of type 2 DM patients is about 
twice compared to patients without DM (Zhou et al., 2005). 
 The United Kingdom Prospective Diabetes Study (UKPDS) reported that 
glycaemic control would be worse. Due to this worsening glycaemic control, it is 
necessary to provide lifestyle intervention, monotherapy oral antidiabetics, followed by 
multiple therapies (Triplit et al., 2006).  Schwartz et al. (2003) reported that patients not 
controlled with lifestyle intervention are given a single antidiabetic. A number of the 
48% of the subjects of the research, who was given glibenclamide, needed additional 
therapy after 6 years. Based on the data from UKPDS, 8%, 42% and 24% of the subjects 
who were given a diet, insulin or sulfonylurea therapy can maintain their HbA1c under 
7% for 9 years. After 3 years of monotherapy treatment, there were around 50% of the 
subjects whose level of HbA1c can be maintained.   
 UKPDS reported that many patients of type 2 DM will need exogenous insulin 
therapy later in their lives. The decrease of insulin secretion is caused by the decrease of 
pancreatic beta cells function so that oral antidiabetics cannot control blood glucose 
levels anymore (Raskin et al., 2005). Type 2 DM patients whose blood glucose control 
are decreasing due to oral antidiabetics can be treated by intensive insulin therapy which 
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can maintain glycaemia, since it can repair insulin secretion and action (Ryan et al., 
2004). UKPDS reported that intensive therapy can reduce clinical risks and it was also 
reported that early addition of insulin to oral therapy can maintain HbA1c at 7% in the 
first six years after diagnosis (Riddle et al., 2003). 
 Schwartz et al. (2003) reported the efficacy of basal insulin addition to patients 
with oral antidiabetics. Twice-daily 70/30 insulin combined with metformin indicated an 
equivalent decrease of HbA1c (around 1.7%) with triple oral therapy (sulfonylurea, 
metformin, and thiazolidinedione), but only one third of the patients from each of the 
therapy groups reach a HbA1c target ≤ 7%. The addition of insulin NPH, once a day, or 
glargine insulin on monotherapy or two combinations-oral antidiabetics can decrease 
HbA1c levels reaching ≤ 7% in 60% patients, in which therapy groups with glargine 
showed a significant decrease of hypoglycemia nocturnal risk.  
 Another research conducted by Rosenstock et al. (2006) concluded that both the 
addition of glargine insulin and the maximum dose of rosiglitazone as a triple therapy 
regimen effectively decrease the HbA1c. Groups with glargine therapy showed the 
decrease of fasting plasma glucose (FPG) in all patients and significant improvements in 
patients with high levels of HbA1c. Compared to rosiglitazone, glargine insulin has more 
potential to initiate hypoglycemia. However, its side effects are less and does not cause 
edema, increase in weight, and it gives a good effect on the lipid profile with low cost 
therapy. 
 Concerning various pathophysiology of type 2 diabetes, the use of 2 to 3 oral 
antidiabetic combinations with different action mechanisms is the most rational measure. 
This regimen does not only repair glycaemic control, but also enable the decrease of the 
whole combination drug dose as well as the decrease of adverse drug reactions (ADR) 
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occurrence (Inzucchi, 2002). However, blood glucose control in the end will be worse 
due to decreasing function of pancreatic beta cells. Monotherapy with oral 
hypoglycaemic agent (OHA) will not be effective for long, thus it is continued by 
therapy combining 2 to 3 types of OHA (Indonesian Association of Endocrinologists, 
2006). In the end, type 2 DM patients will need exogenous insulin therapy (Wright et al., 
2002). However, the decision to switch to insulin therapy is belongs to the patients. 
Patients’ refusal to start insulin therapy is possible due to the pain felt when the insulin 
is injected or the fear of hypoglycemia occurrence (Funnel, 2007). The choice of therapy 
for patient refusing insulin therapy is by maximizing regimens of triple oral therapy by 
means of increasing the dosage or usage frequency. 
 Polypharmacy and the increase of dosage will decrease the safety of therapy due 
to the increase of ADR and over dosage risks. This will effects the patients’ quality of 
life and raise therapy costs (Cipolle et al., 1998). ADR can also become a potential 
contributing factor for patients who do not use the drugs as prescribed, which prevent 
the patients from obtaining optimum therapy (Krska, 2004). Drug-drug interaction can 
lead to hypoglycaemia and disturb patients’ diabetes control as well as make the therapy 
less effective (Baxter, 2006).  
Based on the explanations aforementioned, diabetes mellitus needs to get special 
attention with regard to the increasing incidence of the disease and the potential effects 
on the patients’ quality of life as well as the large increase in medical expenses. 
Therefore, cost-effective therapy is needed in handling type 2 diabetes mellitus.  
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1.2 PROBLEM STATEMENT 
Pharmacy managers, healthcare administrators, and insurers have to play a role 
and consider the increasing medical costs. In order to optimize the medical costs, a 
strategy of therapy management is required by using resources efficiently and 
effectively. Pharmacists encounter a challenge to provide appropriate, effective and 
efficient services by balancing access, costs and quality. To meet this responsibility, a 
related policy is required on the use of appropriate and cost-effective pharmaceuticals 
therapy design. 
Type 2 diabetes is associated with long term complications that ultimately results 
in increased rate of adult blindness, renal failure, and amputation than any other disease. 
In addition, people with type 2 diabetes have an increased risk of stroke and myocardial 
infarction. Mortality rates of people with type 2 diabetes are about twice of those 
without diabetes. Because of the high morbidity, mortality, and costs associated with 
type 2 diabetes, there has been great interest in assessing the impact of medication 
therapy (triple oral therapy and insulin) on effectiveness, safety, quality of life, and cost. 
 
1.3 RATIONALE OF THE STUDY 
Diabetes mellitus is a chronic disorder that has been recognized by the 
Indonesian government as a major public health problem with far reaching consequences 
not just for its adverse impact on the health of Indonesians, but also for the economic 
burden it places on the health care system. Diabetes is ranked as the tenth leading cause 
of death in Indonesia. The number rises dramatically when deaths from diabetic 
complications are included. 
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Diabetes mellitus may affect patients’ quality of life and have a burden on their 
social life. Diabetes may also cause several complications. A long-term complication 
encompasses retinopathy that causes loss of vision, nephropathy that causes kidney 
disease and peripheral neuropathy that causes amputation risks. A diabetes patient has a 
high risk of cardiovascular, peripheral vascular and cerebrovascular diseases. As a 
result, it may increase the economic burden for the diabetes patient, family, and health 
service system and government.  
 The expected achievement of DM therapy is to prevent DM-caused 
complications by maintaining a normal blood glucose level and improving the patient’s 
quality of life. The blood glucose level can be controlled using diet therapy, physical 
exercise, oral hypoglycaemic drug or insulin. The diabetes patient whose blood glucose 
level has not been controlled on a monotherapy oral hypoglycaemic drug or a 
combination, may be given insulin therapy. However, the clinician often needs a rather 
long period to switch the patient from receiving an oral hypoglycaemic drug to insulin. 
The patient’s hesitancy to switch to insulin therapy may be due to several reasons. A 
belief that insulin is for the person whose disease has been severe indicates the patient’s 
failure in managing his/her disease. A belief that insulin is not effective, which may 
appear because a friend or family member who received insulin did not undergo any 
decrease in blood glucose levels, but even gained weight or hypoglycaemia event occurs 
more often. It may also be due to the belief that insulin causes complications, fear of 
pain during injection, fear of occurrence of hypoglycaemia events, and difficulties in 
arranging a schedule and insulin dose, hence the patient keeps using a combination of 
oral antidiabetic drugs.  
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  Research on the comparison of intervention between insulin therapy and triple 
oral therapy on type 2 DM outpatients perceived from the clinical, humanistic and 
economic outcomes have not been conducted in Indonesia. Similar researches have been 
conducted in the United States and European countries, that is, comparing the addition 
of insulin and thiazolidinedione with the combination of sulfonylurea and metformin on 
the patients who had uncontrollable blood glucose levels. A research comparing the 
addition of insulin and acarbose with the combination of sulfonyurea and metformin on 
patients has also been conducted, but only perceived from its efficacy in controlling 
glycaemia. This research compared the addition and switching of therapy to insulin and 
triple oral therapy (sulfonylurea, metformin and acarbose) perceived from three outcome 
parameters, comprising clinical, humanistic and economic outcomes. 
 
1.4 HYPOTHESIS 
1.4.1   Insulin therapy, along with a combination of oral antidiabetics, is more 
effective and safer than triple oral therapy in a type 2 DM patient who has 
blood glucose level not under control. 
1.4.2 Health-related quality of life in type 2 DM patient with poor glycaemic 
control who adds or switches the therapy to insulin is better than in the 
patient who keeps using triple oral therapy. 
1.4.3 In terms of an institutional perspective, the addition or switching of therapy 
to insulin in the patient with poor glycaemic control is more cost-effective 
than triple oral therapy. 
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1.5 OBJECTIVE 
1.5.1 General Aims 
This study aims to compare the effectiveness and safety of two possible 
approaches for managing the failure of combination therapy with oral medication: 1) 
switching treatment to insulin and 2) combination therapy with oral medication for 
patients who are reluctant to initiate insulin; and 3) to estimate direct medical costs and 
cost-effectiveness between the two groups. 
 
1.5.2 Specific Aims 
In order to achieve the general aims, the study has the following objectives: 
(i)  To assess the effectiveness of the diabetes therapy which includes changes from the 
baseline for HbA1c, fasting plasma glucose, postprandial plasma glucose, blood 
pressure, and lipid profiles between two groups (insulin therapy and triple oral 
therapy). 
(ii). To assess safety parameters including general physical examination, clinical 
laboratory evaluations, and report adverse events and hypoglycaemic episodes 
between the two groups. 
(iii). To compare health-related quality of life between the two groups 
(iv). To compare the direct medical costs between the two groups 
(v). To estimate the cost-effectiveness from the hospital perspective, of two possible 
approaches for managing the failure of combination therapy with oral medication 
(switching treatment to insulin vs combination therapy with oral medication for 
patients who are reluctant to initiate insulin). 
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1.6 CONTRIBUTION OF THE STUDY FINDINGS 
 The results of this research can be utilized by pharmacists or clinicians as a 
comparison of effectiveness and costs of type 2 DM therapy management. The data of 
cost-effectiveness and clinical effectiveness from the intervention of adding or giving 
insulin and triple oral therapy can be utilized as a reference in determining the most 
optimum therapy decision on type 2 DM patients. 
 It can be utilized also by institutions and managed care plans as a basis for 
determining the value of pharmaceuticals in order to achieve the expected outcomes. It 
can be used by policy makers as a basis in the formulary system, to put in, take out, with 
or without restrictions, on the related drugs with type 2 DM therapy and diabetes-related 
complications. The formulary system plays an important role in determining the use of 
an accurate drug, cost reduction and quality improvement. Formularies are mainly 
designed to promote the cost-effective use of safe and effective pharmaceutical products. 
In composing and revising the formulary, the selection criteria to choose drug 
alternatives are based on the clinical efficacy, effectiveness, side-effect risks and costs.  
 For the health service system, the research results would be useful for the 
development and justification of drug guidelines and disease management initiatives to 
promote the most appropriate use of medications for type 2 D 
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CHAPTER 2 
LITERATURE REVIEW 
 
 Diabetes mellitus is a severe chronic disease marked by hyperglycaemia caused 
by disturbances in insulin secretion, insulin resistance, or both of them. The incidence of 
diabetes mellitus disease is increasing not only in Indonesia but all over the world. It is 
estimated that 300 million people will suffer from diabetes in 2025 (± 5.4% of world 
population). Type 2 diabetes mellitus represents 90% of all diabetes cases all over the 
world (Kaplan, 2004). Type 2 DM estimates will heavily affect the developing countries 
and will occur not only in the urban population. In the developing countries, DM disease 
also occurs in productive age populations such that it causes loss of human capital and 
productivity (Narayan and Williams, 2009). 
In relation to the increasing prevalence and incidence of type 2 DM, it has been 
identified that the achievement of glycaemic control can decrease morbidity, and 
effective hyperglycaemic therapy management is the main priority. Type 2 diabetes 
mellitus is often related to various other health disturbances such as hypertension, 
dyslipidaemia, hypercoagulability, and abdominal obesity. It is often called as  
metabolic syndrome or insulin resistance syndrome (Carlisle et al., 2005; Nathan et al., 
2009).  
The target of DM therapy is to prevent and to impede the occurrence of 
complications, by keeping the blood glucose level in the normal range. The United 
Kingdom Prospective Diabetes Study (UKPDS) reported that an increase of HbA1c by 
only 1%, can increase the risk of microvascular complications as much as 35% (Triplitt 
et al., 2005). In type 2 DM patients, more intensive treatment strategies can decrease the 
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occurrence of microvascular complications. An effective therapy strategy is always 
developed to increase the glycaemic control in DM patients for the purpose of 
preventing or delaying the occurrence of complications and increasing the patients’ 
quality of life. To determine the appropriate therapy regimen in patients, the cost-
effectiveness, efficacy as well as safety must be taken into consideration. 
 
2.1 HYPERGLYCAEMIC THERAPY MANAGEMENT IN TYPE 2 DIABETES 
MELLITUS 
 Diabetes mellitus is marked by the increase in blood glucose levels caused by the 
metabolic abnormality of carbohydrate, fat, and protein. The diabetic condition is caused 
by inadequate insulin supply or inadequate tissue response toward insulin. The following 
is the explanation of the pathogenesis.  
 
2.1.2 Pathogenesis of Type 2 Diabetes Mellitus 
 Type 2 diabetes mellitus is caused by the imbalance between the insulin 
sensitivity in peripheral tissues and the liver and insulin secretion from pancreatic β-
cells. In non-diabetic patients, glucose homeostasis is mediated by insulin secretion 
stimulated from the pancreatic β-cells which will reduce the production of endogenous 
hepatic glucose and stimulate glucose uptake in peripheral tissues. In type 2 DM patients 
who are approximately 90% to 95% of diagnosed diabetes cases, resistance toward 
insulin in the liver and peripheral tissues occurs, and the ability of pancreatic β-cells to 
secrete insulin decreases. The occurrence of insulin resistance causes the pancreas to 
synthesize excessive insulin to metabolize the existing glucose. In the initial stages of 
the disease, type 2 DM patients can increase their insulin secretion. Insulin secretion 
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decreases more and more as time goes by, causing insufficient insulin production to 
maintain blood glucose. Although the pathophysiological process has not been clearly 
identified, the condition of hyperglycaemia has a toxic effect on the function of β-cells 
or causing their apoptosis without being equaled with the increase of pancreatic β-cell 
proliferation. The decrease of pancreatic β-cell function and relative insulin deficiency 
causes glucose intolerance and finally makes diabetes more serious (Bethel and 
Feinglos, 2005; Chitre and Burke, 2006).  
Hyperglycaemia is the main cause of the occurrence of DM complications. The 
disturbing effect is because of the substances derived from sugar and they are known as 
advanced glycation end products (AGEs). AGEs are a heterogenic group of a molecule 
formed from a nonenzymatic reaction of reducing sugar with free amino group from 
protein, lipids, and nucleic acids. The early product of this reaction is called Schiff base 
which spontaneously rearranges itself into an Amadori product which is known as 
glycated haemoglobine (HbA1c). The main characteristic of the precursor and these 
reactive AGEs is the ability to form a covalent bond between proteins which will change 
the function and structure as in a cellular matrix, basement membranes, and vessel-wall 
components. Another main characteristic is that it is able to interact with some cell 
surface AGE-binding receptors causing the occurrence of endocytosis and degradation 
or the activation of cellular, pro-oxidant, and pro-inflammatory pathways(Peppa et al., 
2003). 
2.1.3 Long-term Diabetic Complications 
As the time goes by, diabetes can cause damage and dysfunction in various organ 
systems. Microvascular and macrovascular complications can contributes to the high 
rate of morbidity and mortality of diabetes. 
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(i) Macrovascular complications 
This complication involves coronary artery, peripheral blood vessel, and cerebral 
blood vessel. Cardiovascular disease is the leading cause of mortality and the major 
cause of morbidity in patients with diabetes mellitus. The most common manifestations 
of cardiovascular disease are acute myocardial infarction, angina, heart failure, and 
sudden death. Cardiovascular disease results in a large part from the sequelae of 
atherosclerotic coronary artery disease (CAD) and hypertension, which are highly 
prevalent in patients with type 2 diabetes mellitus (Young and Chyun, 2005). 
Atherosclerotic vascular disease is more common in diabetic
 
than in nondiabetic 
individuals. Both pathologic studies and angiographic reports in individuals
 
with 
coronary heart disease have shown that patients with diabetes
 
have a greater number of 
coronary blood vessels involved with
 
a more diffuse distribution of atherosclerotic 
lesions (Milicevic et al., 2008).  
Peripheral vascular disease (PVD) affects the blood vessels outside the heart. In 
people with diabetes mellitus it often affects the arteries of the legs and may give rise to 
intermittent claudication, a cramping pain experienced on walking, due to reversible 
muscle ischaemia secondary to atherosclerosis. The iliac vessels can be affected, causing 
buttock pain and also erectile dysfunction (Hackett and Thomas, 2007). 
 
(ii) Microvascular complications 
The prevalence of retinopathy is very common in someone suffering from 
diabetes. After 20 years, more than 60% of type 2 DM patients will suffer retinopathy in 
various degrees of criticality. The incidence of diabetic retinopathy is because of the 
microangiopathy occurring in arteriolar retinal pre-capillary, capillary, and venula. The 
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damage is caused by microvascular leakage because of the decomposition of retinal 
barrier so that blood can enter, and the presence of microvascular block (Watkins, 2003). 
Glaucoma, cataract, and other disturbance in the eyes can cause retinopathy and it has to 
be evaluated. 
Diabetic nephropathy occurs in 20-40% of the patients with diabetes and is the 
main cause of terminal kidney failure. Microalbuminuria (30-299 mg/24 hours) is the 
indication of nephropathy occurrence in type 2 DM. Patients with the microalbuminuria 
growing into macroalbuminuria (> 300 mg/24 hours) are likely to develop terminal 
kidney failure in some years (ADA, 2007). Uncontrolled blood pressure will make 
proteinuria more serious. 
Neuropathy increases the morbidity in diabetes, mainly because of its role in the 
pathogenesis of diabetic ulcer (Feingold dan Funk, 2000). In addition to the 
improvement of blood glucose control to make hyperglycaemic damage progression 
slower, a specific medical treatment for the existing hyperglycaemic damage has not 
been available. The manifestations of diabetic autonomic neuropathy such as tachycardia 
in the condition of rest, orthostatic hypotension, gastroparesis, constipation, erectile 
dysfunction, neurovascular function disturbance, and hypoglycaemic autonomic failure 
(ADA, 2007). 
 
2.1.4 Treatment Strategies in Type 2 Diabetes Mellitus 
 Diabetes patients have to get medical services from a well-coordinated team 
which includes physicians, nurse practitioners, physician assistants, nurses, dietitians, 
pharmacists, and mental health professionals with special skills and interests in diabetes. 
It really requires integrated cooperation and approach from the team to make sure that 
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diabetes patients participate actively in it (ADA, 2009). Patients play a very important 
role in the diabetes care team and they have to be trained, given skills and knowledge in 
preventing and handling hypoglycaemia, and also therapy adjustment based on the 
guideline of health care providers to reach glycaemic goals (Nathan et al., 2009).  
 The clinical route of DM disease is marked by a gradual decrease of pancreatic 
β-cell function, so that therapy adjustment is required (Heine et al., 2006). A general 
approach of therapy in type 2 DM begins with diet, exercise, weight control, and 
education. If the blood glucose level has not reached the target, a single antidiabetic can 
be given. The combination of two antidiabetics with different mechanism action can be 
given earlier if serious hyperglycemia occurs, or if monotherapy can not reach or keep 
glycaemic control (Bailey, 2005). 
 
(i) Monotherapy 
 Giving medicine at the beginning of DM therapy is based on some factors 
including patient profile, early blood glucose levels, and economic considerations or 
formulary (Mudaliar and Henry, 2005). In determining a specific antidiabetic, it is 
necessary to consider its effectiveness in decreasing blood glucose levels, a 
extraglycaemic effect that can decrease long-term complications, safety profiles, 
tolerability, and cost (Nathan et al., 2009). Most oral antidiabetics have the same 
efficacy in decreasing HbA1c level, except α-glucosidase inhibitor and nateglinide 
(Kimmel and Inzucchi, 2005).  
Generally, patients with serious hyperglycaemia (> 300 mg/dL), ketonuria, 
ketonemia, pregnant patients, patients with acute myocardial infarction and all acute 
conditions have to be given insulin. In many patients, sulfonylurea or metformin can be 
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given as early therapy and the titration is conducted every one to two weeks according to 
patient response. In elderly patients with irregular eating profiles, the prescription of a 
short-acting secretagogue is suggested rather than sulfonylurea, because it can cause 
hypoglycaemia if the patients forget to eat. In predominant postprandial hyperglycaemia 
patients, the therapy choice is acarbose or miglitol, particularly in patients with high 
carbohydrate intake (Mudaliar and Henry, 2005). Dipeptidyl peptidase-4 (DPP-4) 
inhibitors are new oral antidiabetics which also takes effect in postprandial 
hyperglycaemia, but their half-life is very short (Fowler, 2007).  
 
(ii) Combination Therapy 
 Diabetes is a progressive disease, and combination therapy is at times the only 
way to attain good glycaemic control in many patients (Inzucchi, 2006). If the second 
antidiabetic is added, the synergy of both antidiabetics and the possibility of medicine 
interaction have to be taken into consideration. Generally, antidiabetics with different 
action mechanisms will give bigger synergy (Nathan et al., 2009). 
 The combination of secretagogue and insulin sensitizer can work in synergy and 
is directed to two main pathophysiological abnormalities in diabetes. Therefore, more 
research has been conducted on the combination of sulfonylurea and metformin and it 
has been known that it can decrease additional HbA1c level as high as 1.7%. Another 
alternative is the combination of sulfonylurea or metformin with thiazolidinedione. The 
combination of metformin and thiazolidinedione provides better efficacy because this 
combination also improves the main pathophysiological abnormality of DM. Metformin 
acts by decreasing hepatic glucose production, while the action of thiazolidinedione is 
particularly in insulin resistance in muscle and adipose tissues. The addition of acarbose 
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with sulfonylurea or metformin is a chosen alternative of a combination of drugs to 
improve glycaemic control, particularly in postprandial hyperglycaemia. If combination 
therapy with two oral agents does not achieve the desired goal, available options include 
(1) adding a third oral agent; (2) adding bed time insulin while maintaining therapy with 
one or both oral agents; or (3) switching the patient to a mixed-split insulin regimen 
(Mudaliar and Henry, 2005). 
 
(iii) Insulin Therapy 
 There are some factors that need to be considered in determining an insulin 
regimen for individual patients. These factors can be categorized into two, namely 
patient factors and glycaemic factors. Before starting insulin therapy regimen, assessing 
patient factor needs to be conducted, that is, willingness to implement a specific insulin 
regimen, comfort level, ability (visual acuity, dexterity, and cognitive skills), and 
lifestyle factors (eating habits, physical activity, and schedule). 
There are three insulin regimens that can be used to begin insulin therapy in type 
2 DM patient, that is, basal insulin with oral antidiabetic, premixed insulin, or giving 
basal insulin with postprandial insulin. In insulin therapy regimen, therapy with basal 
and postprandial insulin is gold standard, but in using this regimen, the motivation of the 
patient must be high and enough time is needed to give support, education and follow up 
to the patient (Pearson and Powers, 2006).  
Today, the use of background insulin with oral antidiabetic agents is a relatively 
common approach to initiating insulin therapy. Fasting glucose levels are targeted with 
background insulin and oral agents address mealtime glucose excursions. A second 
insulin regimen consists of premixed insulin given twice a day. This treatment approach 
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can include the use of insulin sensitizers (metformin, pioglitazone, rosiglitazone). A 
background and mealtime insulin regimen consists of a long-acting insulin as the 
background insulin with a rapid- or short-acting insulin taken at mealtime. This regimen 
most closely mimics the normal physiological insulin response to food intake (Pearson 
and Powers, 2006). 
 
Figure 2.1 Initiation and adjustment of insulin regimens (Nathan et al., 2009) 
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The insulin initiation algorithm  recommends starting with bedtime intermediate-
acting insulin or bedtime or morning long-acting insulin. An initial dose could be either 
10 U or 0.2 U/kg (Fig. 2.1). Table 2.1 shows the types of insulin available in Indonesia. 
NPH (Neutral Protamine Hagedorn ) insulin more often causes nocturnal hypoglycaemia 
to occur than long-acting insulin. Some type 2 DM patients with HbA1c value of ≤ 9% 
and high fasting blood glucose levels can reach HbA1c value of < 7% by adding basal 
insulin analog. If blood glucose levels are in the target range (70 – 130 mg/dL) and 
HbA1c value is above therapy target, the blood glucose level has to be evaluated and the 
patient can be given an additional second dosage of prandial insulin to reach glycaemic 
target. The dosage of prandial insulin can be titrated by evaluating postprandial glucose 
level (Blonde, 2007).  
The American Diabetes Association and the European Association for the Study 
of  Diabetes have published a consensus statement on the approach to management of 
hyperglycaemia in type 2 DM patients (Nathan et al., 2009). Figure 2.1 are the therapy 
algorithm recommended in the consensus. 
The different types of insulin are based on onset, duration of action, source, 
pureness, concentration, and solubility. Table 2.1 shows the classification of insulin 
based on duration of action. In the past, insulin therapy for type 2 DM patients was 
regarded as a last choice but this paradigm begins to experience some shift as time went 
by. A research conducted by Ryan et al. (2004) shows that short-term intensive insulin 
therapy in newly diagnosed type 2 DM patients may increase blood glucose control for a 
long time.  
 
 
23 
 
Table 2.1. Description of onset, peak, and duration of insulins  
 
Insulins Onset Peak Duration 
Short-acting insulin 
Regular (Actaprid
®
, Humulin
®
R) 
 
 
30-60 minutes 
 
30-90 
minutes 
 
3-5 hours 
Analog rapid-acting insulin 
Insulin lispro (Humalog
®
) 
Insulin glulisine (Apidra
®
) 
Insulin aspart (NovoRapid
®
) 
 
 
5-15 minutes  
5-15 minutes 
5-15 minutes 
 
30-90 
minutes 
30-90 
minutes 
30-90 
minutes 
 
3-5 hours 
3-5 hours 
3-5 hours 
Intermediate-acting insulin 
NPH (Insulatard
®
, Humulin
®
N) 
Lente 
 
 
2-4 hours 
3-4 hours 
 
4-10 hours 
4-12 hours 
 
10-16 hours 
12-18 hours 
Long-acting insulin 
Insulin glargine (Lantus
®
) 
 
Ultralente 
Insulin detemir (Levemir
®
) 
 
 
2-4 hours 
 
6-10 hours 
2-4 hours 
 
peakless  
 
8-10 jam 
peakless 
 
- 
 
- 
- 
Combinations 
(short- and intermediate-acting) 
 
70% NPH/ 30% regular (Mixtard
®
, 
Humulin
®
30/70) 
70% insulin aspart protamine/30% 
insulin aspart (NovoMix
®
30) 
75% insulin lispro protamine/25% 
insulin lispro injeksi(Humalog
®
 Mix 
25) 
 
 
 
30-60 minutes 
10-20 minutes 
5-15 minutes 
 
 
 
Dual 
 
Dual 
 
1-2 hours 
 
 
 
10-16 hours 
 
15-18 hours 
 
16-18 hours 
 Source : Indonesian Association of Endocrinologists (2006)  
The unwillingness of patients to change to insulin therapy is probably caused by 
many things. Common barriers among patients include beliefs that insulin is a personal 
failure, that insulin is not effective, that insulin causes complications or even death, or 
that insulin injections are painful, as well as fear of hypoglycemia, loss of independence, 
weight gain, and cost (Funnel, 2004 ; Meece, 2006). 
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(iv) Type 2 Diabetes Mellitus Treatment Algorithm 
 Therapy in type 2 DM patients who have just been diagnosed begins with 
lifestyle interventions. Lifestyle intervention can improve blood glucose level, blood 
pressure, lipid level, and can decrease weight or prevent weight increase. Therapy with 
metformin can be given together with lifestyle intervention at the time of diagnosis (Fig. 
2.2). Metformin is recommended to be given as the first line therapy in non 
contraindicated patients because of its advantageous effect on blood glucose levels, for 
not causing weight increase and hypoglycaemia. Moreover, side effects seldom occur, 
there is a high level of acceptance, and it is relatively low cost. Metformin dosage can be 
titrated to effective maximum dosage every 1 to 2 months.  
If lifestyle intervention and a maximal tolerated dose of metformin fail to reach a 
glycaemic target, other antidiabetics can be added in 2 to 3 months of early therapy, or 
when the HbA1c level target is not reached. If in lifestyle intervention, metformin and 
sulfonylurea or basal insulin cannot reach a glycaemic target, the next step is giving 
insulin intensively. The intensification of giving insulin is conducted by adding short or 
rapid acting insulin given before eating to reduce the increase of postprandial blood 
glucose. If insulin is given, insulin secretagogue must be stopped or decreased because it 
does not give a synergic effect. Although the addition of a third oral antidiabetic can be 
considered, particularly in HbA1c level of >8%, this approach is less effective in 
decreasing blood glucose levels and more expensive than giving therapy intensification 
with insulin (Nathan et al., 2009). 
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Figure 2.2 Glycaemic control algorithm for type 2 DM in children and adults 
(Triplitt et al., 2005) 
 
 
2.1.5 The Effectiveness and Safety of Antidiabetics 
 The selection of specific antidiabetics is based on its effectiveness in decreasing 
blood glucose levels, extraglycaemic effects that can decrease long term complications, 
safety profile, tolerability, ease-of-use and expense (Nathan et al., 2009). Each of the 
antidiabetics has similarities and differences in the side effects, contraindications, and 
interaction with other medicines. The effects of antidiabetics can be increased by giving 
